Lung Cancer
Volume 70, Issue 1 , Pages 37-42 , October 2010

Chemoprevention of murine lung cancer by gefitinib in combination with prostacyclin synthase overexpression

  • Robert L. Keith

      Affiliations

    • Veterans Administration Medical Center, Division of Pulmonary Sciences and Critical Care Medicine, Denver, CO 80220, United States
    • University of Colorado Denver, Department of Medicine, Denver, CO 80262, United States
    • ,
  • Vijaya Karoor

      Affiliations

    • University of Colorado Denver, Department of Medicine, Denver, CO 80262, United States
    • ,
  • Anthony B. Mozer

      Affiliations

    • Veterans Administration Medical Center, Division of Pulmonary Sciences and Critical Care Medicine, Denver, CO 80220, United States
    • ,
  • Tyler M. Hudish

      Affiliations

    • Veterans Administration Medical Center, Division of Pulmonary Sciences and Critical Care Medicine, Denver, CO 80220, United States
    • ,
  • Mysan Le

      Affiliations

    • Veterans Administration Medical Center, Division of Pulmonary Sciences and Critical Care Medicine, Denver, CO 80220, United States
    • ,
  • York E. Miller

      Affiliations

    • Veterans Administration Medical Center, Division of Pulmonary Sciences and Critical Care Medicine, Denver, CO 80220, United States
    • University of Colorado Denver, Department of Medicine, Denver, CO 80262, United States
    • Corresponding Author InformationCorresponding author at: Department of Medicine, Denver VA Medical Center, 1055 Clermont St., Pulmonary 111A, Denver, CO 80220, United States. Tel.: +1 303 393 2869; fax: +1 303 393 4639.

Received 11 September 2009 ,Revised 9 December 2009 ,Accepted 6 January 2010.

References 

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin. 2009;59:225–249
  2. Tong L, Spitz MR, Fueger JJ, Amos CA. Lung carcinoma in former smokers. Cancer. 1996;78:1004–1010
  3. Malkinson AM. Primary lung tumors in mice as an aid for understanding, preventing, and treating human adenocarcinoma of the lung. Lung Cancer. 2001;32:265–279
  4. Stearman RS, Dwyer-Nield L, Zerbe L, Blaine SA, Chan Z, Bunn PA, et al. Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. Am J Pathol. 2005;167:1763–1775
  5. Keith RL, Miller YE, Hoshikawa Y, Moore MD, Gesell TL, Gao B, et al. Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer. Cancer Res. 2002;62:734–740
  6. Keith RL, Miller YE, Hudish TM, Girod CE, Sotto-Santiago S, Franklin WA, et al. Pulmonary prostacyclin synthase overexpression chemoprevents tobacco smoke lung carcinogenesis in mice. Cancer Res. 2004;64:5897–5904
  7. Nemenoff R, Meyer AM, Hudish TM, Mozer AB, Snee A, Narumiya S, et al. Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator-activated receptor gamma. Cancer Prev Res. 2008;1:349–356
  8. Merrick DT, Kittelson J, Winterhalder R, Kotantoulas G, Ingeberg S, Keith RL, et al. Analysis of c-ErbB1/epidermal growth factor receptor and c-ErbB2/HER-2 expression in bronchial dysplasia: evaluation of potential targets for chemoprevention of lung cancer. Clin Cancer Res. 2006;12:2281–2288
  9. Jonsson S, Varella-Garcia M, Miller YE, Wolf HJ, Byers T, Braudrick S, et al. Chromosomal aneusomy in bronchial high-grade lesions is associated with invasive lung cancer. Am J Respir Crit Care Med. 2008;177:342–347
  10. Kurie JM, Shin HJ, Lee JS, Morice RC, Ro JY, Lippman SM, et al. Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin Cancer Res. 1996;2:1787–1793
  11. Tang X, Shigematsu H, Bekele BN, Roth JA, Minna JD, Hong WK, et al. EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res. 2005;65:7568–7572
  12. Yan Y, Lu Y, Wang M, Vikis H, Yao R, Wang Y, et al. Effect of an epidermal growth factor receptor inhibitor in mouse models of lung cancer. Mol Cancer Res. 2006;4:971–981
  13. Fujimoto N, Wislez M, Zhang J, Iwanaga K, Dackor J, Hanna AE, et al. High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. Cancer Res. 2005;65:11478–11485
  14. Kishino D, Kiura K, Takigawa N, Katayama H, Kuyama S, Sato K, et al. Effect of gefitinib on N-nitrosamine-4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced lung tumorigenesis in A/J mice. Lung Cancer. 2009;65:284–289
  15. Ohashi K, Rai K, Fujiwara Y, Osawa M, Hirano S, Takata K, et al. Induction of lung adenocarcinoma in transgenic mice expressing activated EGFR driven by the SP-C promoter. Cancer Sci. 2008;99:1747–1753
  16. Ohashi K, Takigawa N, Osawa M, Ichihara E, Takeda H, Kubo T, et al. Chemopreventive effects of gefitinib on nonsmoking-related lung tumorigenesis in activating epidermal growth factor receptor transgenic mice. Cancer Res. 2009;69:7088–7095
  17. Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, Ravdel L, et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res. 2006;66:944–950
  18. Wick M, Hurteau G, Dessev C, Chan D, Geraci MW, Winn RA, et al. Peroxisome proliferator-activated receptor-gamma is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth. Mol Pharmacol. 2002;62:1207–1214
  19. Geraci MW, Gao B, Shepherd DC, Moore MD, Westcott JY, Fagan KA, et al. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. J Clin Invest. 1999;103:1509–1515
  20. Zerbe LK, Dwyer-Nield LD, Fritz JM, Redente EF, Shroyer RJ, Conklin E, et al. Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice. Cancer Chemother Pharmacol. 2008;62:605–620
  21. Zhang X, Chen ZG, Choe MS, Lin Y, Sun SY, Wieand HS, et al. Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res. 2005;11:6261–6269
  22. Zhang X, Zhang H, Tighiouart M, Lee JE, Shin HJ, Khuri FR, et al. Synergistic inhibition of head and neck tumor growth by green tea (−)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor. Int J Cancer. 2008;123:1005–1014
  23. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst. 1999;91:1194–1210
  24. Mueller KL, Hunter LA, Ethier SP, Boerner JL. Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells. Cancer Res. 2008;68:3314–3322
  25. Qin B, Ariyama H, Baba E, Tanaka R, Kusaba H, Harada M, et al. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells. Cancer Chemother Pharmacol. 2006;58:577–584
  26. Zhang J, Kalyankrishna S, Wislez M, Thilaganathan N, Saigal B, Wei W, et al. SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Am J Pathol. 2007;170:366–376

☆ Supported by Department of Veterans Affairs Merit Review Grants (YEM and RLK) and NCI P50 CA58187 (SPORE in Lung Cancer, YEM and RLK).

PII: S0169-5002(10)00006-1

doi: 10.1016/j.lungcan.2010.01.004

Lung Cancer
Volume 70, Issue 1 , Pages 37-42 , October 2010

Article Tools

* Image Usage & Resolution